MedTrace Logo

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

NCT06249633 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-02-08

No results posted yet for this study

Summary

Open-label pilot study of early inhaled nitric oxide (iNO) for patients developing de novo pulmonary hypertension during Acute Respiratory Distress Syndrome (ARDS.) The study aims to determine whether iNO has possible hemodynamic and clinical benefits when given early in the course of ARDS to patients with evidence of elevated pulmonary artery pressure.

Conditions

  • Acute Respiratory Distress Syndrome
  • Pulmonary Hypertension

Interventions

DRUG

Nitric Oxide

Inhaled nitric oxide

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Yuri Matusov

    lead OTHER

Principal Investigators

  • Yuri Matusov, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2026-02-28
Completion
2026-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06249633 on ClinicalTrials.gov